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Abstract 
 
 
 
 
Objective: To determine whether ultrafiltration can be used as primary treatment of 
Congestive Heart Failure. 
 
Study Design: Review of three English language, non-blinded randomized controlled 
trials from 2005, 2007 and 2008.  
 
Data Sources: Randomized, controlled, non-blinded clinical trials comparing 
ultrafiltration to intravenous diuretics found using Ovid Medline and PubMed databases. 
 
Outcome measured: Weight loss after 48 hours was measured at discharge, and at days 
10, 30, and 90 post-discharge. Dyspnea after 48 hours was measured as a perception of 
the patient on a scale from 1 to 7, 1 being markedly worse, 7 being marked improvement. 
Net fluid loss after 48 hours was measured as ultrafiltrated in the ultrafiltration group and 
as urine output in the intravenous diuretic and usual care groups. Finally, 
rehospitalizations for heart failure-related issues was measured, starting on the day of 
discharge through 90 days post-discharge.  
 
Results: There were statistically significant results for weight loss during hospitalization, 
and the p-value for rehospitalization for symptoms of heart failure 90 days post-treatment  
was < 0.05. Net fluid loss over 48 hours was didn’t prove to be significant. Hypotension 
was the most frequent adverse event reported, but was not reported consistently 
throughout all three studies; one study didn’t report adverse events at all.  
 
Conclusions: The studies have proven ultrafiltration to be a safe alternative to intravenous 
diuretics for the treatment of congestive heart failure but there is not enough consistent, 
significant data to say that it can be used as initial primary treatment. Further studies with 
larger and more specific sample populations need to be done in order to better prove true 
long-term efficacy and cost-effectiveness. 
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Introduction: 
 
Congestive Heart Failure is a growing health concern for the aging and elderly 
population in the United States.  Heart Failure is the mechanical failure of the heart and 
occurs when it is no longer able to pump blood at an output sufficient enough to meet the 
metabolic demands of the entire body.
1
 It should be noted that there are many different 
subtypes of heart failure but the common thread is the profound decrease in cardiac 
output. More specifically, ventricular remodeling and neurohormonal activation of the 
sympathetic nervous system as well as the renin-angiotensin-aldosterone system are 
enormous players in the pathophysiology of heart failure.
1 
This pathophysiology leaves 
the patient with symptoms of fatigue, orthopnea, a chronic non-productive cough, 
peripheral edema, and dyspnea on exertion or at rest, depending on severity. All 
symptoms are the result of hypervolemia; an environment primarily created by the 
neurohormones from the kidneys that increase retention of water and sodium.
1
 Fluid 
regulation, therefore, is the primary target of heart failure treatment.
1
 This paper focuses 
on three randomized controlled trials (RCTs) that evaluated the overall efficacy of 
ultrafiltration as primary treatment for congestive heart failure and its ability to decrease 
recidivism as well as cost by decreasing hospital stay. 
Congestive heart failure is of major relevance to the Physician Assistant practice 
because it is a wide and growing diagnosis. 5.8 million people in the U.S. have heart 
failure with approximately 10 per 1000 people being diagnosed after 65 years of age.
2
 1 
in 5 patients die within the first year of diagnosis.
2
 Ultrafiltration has the potential to offer 
patients decreased hospital stays, less recidivism, and longer lifespan.
2
 Heart failure is the 
leading cause of hospitalization in patients > 65 years of age and 65% are re-hospitalized 
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in a one-year period.  In addition, the most common causes of heart failure are three of 
the most common disease processes that Physician Assistants in any field of medicine 
may encounter in their careers: Coronary Artery Disease, Hypertension and Diabetes.  In 
2010, heart failure was estimated to cost $39.2 billion.
2
 The estimated 3.4 outpatient 
visits per heart failure patient per year contribute to the extensive cost.
2
 
Approximately 90% of the annual hospitalizations for heart failure are the result 
of patients suffering the symptoms of volume overload.
3
 Current treatment 
recommendations are aimed towards achieving euvolemia, most commonly treated with 
intravenous diuretics.
3
 More and more hospitals, however, are trying ultrafiltration due to 
the prevalence of diuretic resistance and post-diuretic sodium retention. Post-diuretic 
sodium retention results in inadequate diuresis and the return of hypervolemia 
symptoms.
3
 
An overwhelming 88% of patients are treated with intravenous diuretics and 
sodium restriction from diet.
4
 While intravenous diuretics can be effective for congestive 
heart failure, ultrafiltration is being proposed as primary treatment here because fluid 
removal by this process can improve cardiac output and renal perfusion without altering 
glomerular filtration rate, NaCl uptake in the kidneys or renin secretion as intravenous 
diuretics tend to do.
3
 Ultrafiltration is also being proposed as primary treatment because 
heart failure patients may require less hospitalization time over the course of their 
disease. 
Objective:  
The objective of this review is to determine if ultrafiltration can, in fact, be an 
effective alternative as primary treatment for congestive heart failure patients.  Previously 
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studied randomized controlled trials have suggested that ultrafiltration can produce 
greater fluid loss and maintain this fluid loss at 90 days from the time of treatment, 
thereby decreasing recidivism.
5
 
Methods: 
 All three randomized controlled trials utilized for this review were selected 
because their population group included hospitalized heart failure patients greater than 18 
years of age. The interventions used for these heart failure patients was ultrafiltration and 
the comparison group was heart failure patients treated with intravenous loop diuretics 
such as 20mg Furosemide, 10mg Torsemide, and 1mg Bumetanide.  
 Information obtained for this review was found using both Ovid Medline and 
PubMed databases. Inclusion criteria included randomized controlled trials limited to the 
English language and published data. The keywords used were “Heart Failure”, “CHF”, 
and “Ultrafiltration”.  Further inclusion criteria was based on relevance and whether or 
not the outcomes evaluated in the studies dealt with POEMS (patient oriented evidence 
that matters).  Exclusion criteria included DOEMs (disease oriented evidence that 
matters) and studies that were not previously used in any systematic review or meta-
analysis found on the Cochrane Database. Studies were not excluded based on lack of 
statistical significance. Ultimately, three studies were found and analyzed and they 
included: 1) a randomized, non-blinded, multicenter controlled trial comparing 
ultrafiltration to intravenous diuretics in patients hospitalized with heart failure, 2) a 
randomized, non-blinded controlled trial comparing the renal effects of ultrafiltration to 
those of intravenous furosemide, and 3) a randomized, non-blinded controlled trial 
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comparing ultrafiltration to “usual care” consisting of intravenous furosemide and 
intravenous inotropes.  
 Outcomes measured in all three trials dealt with patient oriented evidence that 
mattered to the patients. For example, in all three studies, weight loss was measured after 
48 hours, at discharge, and at 10, 30 and 90 days post-discharge for both the 
ultrafiltration and the intravenous diuretic groups. Dyspnea was also noted after 48 hours 
and measured as a perception of the patient on a scale from 1 to 7; 1 being markedly 
worse.
5
 In addition, a 6-minute walk distance was performed to also measure dyspnea. 
The ultrafiltrate removed was measured right at the patient’s bedside. This value was 
recorded as net fluid loss after 48 hours. For the intravenous diuretic and usual care 
groups, this value was recorded as urine output. The final outcome measured that 
mattered to patients was the number of re-hospitalizations within a 90-day period for 
heart failure related issues.
5
 
Results: 
 Major demographics and characteristics of the studies utilized for this review are 
displayed in Table 1. It can be noted that all three studies had very similar inclusion 
criteria, including: 2+ pitting lower extremity edema, jugular venous distention, ascites, 
pulmonary edema or pleural effusion, and  2-pillow orthopnea. All patients were older 
than 18 and being hospitalized for congestive heart failure at the time of the study.   
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Table 1 – Demographics & Characteristics of included studies: 
Characteristics of studies included in Systematic Review of the effectiveness of Ultrafiltration as 
primary treatment for Congestive Heart Failure. 
Study Type #Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Bart et al., 
2005 
RCT 40 > 18 2+ edema of 
LE  at least 
one of the 
following:  
elevated JVD, 
pulm edema, 
pleural 
effusion, 
ascites 
Severe stenotic 
valvular disease, 
ACS, Systolic 
BP < 90mmHg, 
HCT > 40%, 
poor peripheral 
venous acces 
Hemodyn 
instability  
2 Pts randomized to 
receive Ultrafiltration 
x 24-48hrs +/- 
1. ACE-Is/ARBs 
2. B-Blockers 
3. Digoxin 
4. Nesiritide 
 
Constanzo, 
et al., 2007 
RCT 200 > 18  Age > 18 & at 
least 2 of the 
following: 
2+ peripheral 
edema; 
JVD > 7 cm; 
Ascites; 
Pulm edema 
or pleural 
effusion; 
Rales or PND 
 
ACS 
Unattainable 
venous access 
Systolic BP < 90 
mmHg 
Serum 
Creatinine > 3 
HCT > 45% 
Vasoactive drug 
use 
Systemic 
infection 
Heart transplant 
20 Pts randomized to 
receive Ultrafiltration 
x 48 hrs  
Rogers, et 
al., 2008 
RCT 26 > 18  Age > 18 
EF < 40% 
> 2+ pitting 
edema of LE 
JVP > 10 cm 
Ascites 
PND 
>  2 pillow 
orthopnea 
Pulm edema 
or Pleural 
effusion 
 
 
 
ACS 
Systolic BP < 
90mmHg 
Serum creatinine 
> 3 mg/dL 
HCT > 45% 
Unattainable 
venous access 
Clinical 
instability likely 
to require 
nitrprusside. 
 
5 Pts randomized to 
receive Ultrafiltration 
x 48 hrs +/- * 
1. ACE-Is/ARBs 
2. B-Blockers 
3. Spironolactone 
4. Digoxin 
*only used if pts were on 
these meds prior to 
hospitalization 
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Table 2 outlines the main endpoints measured in the Costanzo 2007 study which 
compared ultrafiltration (UF) to intravenous diuretics (IVD) for symptom management 
and number of rehospitalizations for congestive heart failure symptoms.  Weight loss, 
dyspnea and rate of recidivism are all endpoints that are both extremely important and 
evident to patients. One of the primary objectives of the study was to show that in 
hypervolemic patients hospitalized with congestive heart failure, ultrafiltration can 
produce greater weight loss over a given period of time versus intravenous diuretics. At 
48 hours, weight loss was greater in the ultrafiltration group than in the intravenous 
diuretic group with a statistically significant p-value of 0.001, evaluated with the 
Wilcoxon’s rank sum test.5  
Dyspnea scores rated by patients on a scale of 1 through 7, 1 being markedly 
worse and 7 being markedly better, proved similar between the UF and IVD groups, with 
the mean dyspnea scores being 5.4 and 5.2 respectively leaving a p-value lacking 
statistical significance (0.588).  Finally, at 90 days post-discharge, the UF group had 16 
of 89 patients rehospitalized (18%) versus the IVD group with 28 of 87 being 
rehospitalized (32%) for CHF-related symptoms, giving a p-value approaching statistical 
significance at 0.037%, calculated with the Kaplan-Meier analysis. Although the relative 
risk reduction or relative benefit increases could not be calculated here for weight loss or 
dyspnea, we were able to see a 20.6% relative benefit increase for UF patients calculated 
based on the number of patients in the study that were not rehospitalized for CHF-related 
symptoms. 
5
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Table 2.  Comparison of weight loss and dyspnea scores in pts after 48 hours and 8 hours 
respectively between UF and IV Diuretics and how volume reduction affects recidivism.  
 
Costanzo 2007 
Mean weight loss and dyspnea scores evaluated by Wilcoxon rank sum test and the 
beneficial effects of UF v IVD on rehospitalization.  
 
 Baseline  
UF
a
  
Baseline 
 IVD
b
 
UF 
Wt Loss 
IVD 
Wt Loss
 
P-value 
Weight (kg) 101  27 96  29 5.0  3.1 3.1  3.5 0.001 
 
 Baseline 
UF 
Baseline 
IVD 
UF IVD P-value 
*Dyspnea Score 
 (1-7) 
 
 
3-7 1-7  5.4  1.1 5.2  1.2 
 
 
0.588 
 
 Baseline  
Pre-UF 
Baseline 
Pre-IVD 
90 days 
post -
UF 
90 days 
post -
IVD 
P-
value 
RBI
c
 ABI NNT 
Hospitalizations 
for CHF 
1.6 1.9 1.5  1.7 18% 32% 0.037 20.6% 14% 8 
* Dyspnea scores were measured from 1 through 7; 1 being markedly worse and 7 being 
markedly better 
a 
UF – Ultrafiltration 
b 
IVD – Intravenous Diuretics 
c
RBI, ABI & NNT values were calculated based on “# of CHF patients not rehospitalized 
for CHF symptoms”.  
 
In Table 3 we see the effect of UF and IVD on fluid loss after 48 hours as 
reported in the Rogers 2008 study. This study pointed out that some patients may have 
diuretic resistance and this could account for the difference in renal function and 
subsequently fluid removal in the Furosemide group versus UF. All continuous variables 
in this study were reported as mean  standard deviation. The group comparisons were 
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made using a paired t-test (2-tailed) and differences between the treatment groups 
evaluated with the Fisher exact test.  For net fluid removal at 48 hours, which included 
urine output plus ultrafiltrate for the UF group, p = 0.682 and for weight loss p = 0.85 as 
the numbers between the UF and Furosemide groups were very similar, and therefore, not 
statistically significant.
3
 
Table 3.   Effect of UF and IVD on Fluid Loss after 48 hours 
Rogers 2008 
Fluid Loss and subsequent weight loss of CHF patients given IV Furosemide vs UF 
 
 UF IVD
a
 P-value
b
 
*Net Fluid 
Loss 
5864  2414 5786  2587  0.682 
 
 UF IVD P-value 
Weight Loss 
 
2.2   2.6  1.9  2.7 0.850 
*Net Fluid loss was measured in mL as total urine output after 48 hrs for IVD group and 
as ultrafiltrate plus urine output for the UF group.  
a 
Furosemide dose over 48 hrs ranged from 240-520mg  
b 
P-values: Unpaired t-test was used for comparisons between treatment groups and 
differences were evaluated with the Fisher exact test. RRR, ARR, and NNT values could 
not be calculated due to having only continuous data.  
 
 Table 4 shows results from Bart 2005. Although this study was ultimately 
measuring weight loss, the p-value ended up not being statistically significant (0.240). 
UF proved more favorable, however, for reduction of dyspnea (p = 0.039) and global 
CHF symptoms (p= 0.023) suggesting that fluid removal may be more effective with UF 
vs. usual care methods such as IV diuretics and inotropes.
4
  In addition, 56.3% of UF 
patients reported “marked improvement” in global CHF symptoms versus 18.8% in the 
usual care group, and 31.3% of those treated wth UF reported “marked improvement” 
with dyspnea compared to 18.8% of those treated with usual care.
4
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Table 4.   Symptom reduction comparisons in CHF patients treated with UF and “usual 
care” 
Bart 2005 
Percent of persons who reported improvements or no change in CHF symptoms, 
specifically dyspnea, after 48 hours of treatment. 
 
Global CHF 
Sx 
UF UC
a 
P-value
b
 RBI ABI NNT 
Marked 
Improvement 
56.3% 18.8% 0.023 18.1% 10.5% 10 
No Change 6.3% 18.8% 
 
Dyspnea Sx UF UC P-value RBI 
 
ABI NNT 
Marked 
Improvement  
 
31.3% 12.5% 0.039 55.5% 26.3% 4 
No Change 6.3% 37.5% 
a – UC = Usual Care group was treated primarily with IV diuretics, but IV inotropes were 
also used in several patients.  
b – P-values: Two-sided Wilcoxon rank sum test was used since this data was continuous. 
 
Table 5 shows adverse events and NNH values. Only two of the three trials used 
included information about adverse events along with their data. Common to both studies 
was infection related to catheter site and occurred in 1 of 19 patients in the Bart 2005 
study and in 1 of 89 in the Costanzo 2007 study; both events were minor and did not 
exclude that person from the study.
4,5
 Catheter-related infection was the only adverse 
event reported in the 2005 study. Hypotension was the most commonly reported adverse 
event in Costanzo 2007, though no one dropped out of the study or was excluded 
because of it. Other adverse events reported in the 2007 study were worsening heart 
failure, cardiac arrest, arrhythmias, and anemia, but it is impossible to pinpoint UF or 
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IVD as the causative factor of these events, especially taking into consideration the 
baseline health status of the patients enrolled in the clinical trial.
5
  
Table 5.  *Adverse Events 
Costanzo 2007  
N=89 (UF), N= 87 (IVD) 
Bart 2005 
N=19 (UF), N=19 (Usual Care) 
 
 UF IVD UF UC 
Infection (catheter-
related) 
1 (1%) 0 1 (5%) 0 
Hypotension 22 (25%) 10 (11%)   
Arrhythmias 
 
10 (11%) 6 (7%)   
Cardiac arrest  4 (4%) 6 (7%)   
NNH 8  
Hypotension 
- 19 
Infection 
Catheter-related 
- 
*Adverse events were not reported in Rogers 2008 study 
 - events not reported in study 
 
Discussion:  
Ultrafiltration is a non-drug based treatment option for congestive heart failure 
that can remove up to 1 lb per hour of excess volume from the blood. It can be compared 
to dialysis in that blood is moved extracorporeally, filtered of only sodium and water, and 
then returned to the body. The volume of blood cycled is, however, much less compared 
to hemodialysis leading to less incidence of hemodynamic instability. 88% of heart 
failure patients are currently being treated with intravenous diuretics but many patients 
develop diuretic resistance.
4
 It is for these patients that ultrafiltration is currently being 
utilized most. The machine attached peripherally to the patient filters the blood through a 
semipermeable membrane by way of a pressure gradient system. The rate at which fluid 
is removed through the semipermeable membrane can be selected based on the patients’ 
hemodynamic conditions. If patients become hypotensive, which did occur in the 
Tallis; CHF & Ultrafiltration 10 
   
Costanzo 2007 trial, it is possible to slow the rate of blood flow or ultrafiltration to avoid 
hemodynamic instability.
6
 
While the costs of ultrafiltration exceed those of intravenous diuretics inititally, 
the thought is that reduction in length of hospital stays and decreased rates of recidivism 
will actually even out the cost discrepancy between the two treatment modalities. 
Monetary information, though very relevant, was not mentioned in any of the three RCTs 
studied. 
All RCTs effectively demonstrated that in heart failure patients with volume 
overload, ultrafiltration results in greater fluid removal and is not associated with harmful 
adverse events. The most obvious limitations to all RCTs studied were the very small 
sample sizes. Furthermore, a more defined sample population needs to be studied to 
accurately determine rate of rehospitalization. The admission criteria utilized for these 
RCTs was very broad. Hospital readmission rates, for example, might be less favorable if 
the population studied were restricted to only class IV heart failure patients.  
Conclusion:  
 While ultrafiltration has proven to be a safe alternative to intravenous diuretics for 
the treatment of heart failure, there is not enough consistent, significant data to say that it 
can be used as primary treatment. Further studies with a larger, yet more refined sample 
populations should be included. The age requirement should be 65 and older to better 
reflect the core heart failure population.  Studies should further split intervention groups 
into the NYHA classes of heart failure III and IV. These changes will aid in proving true 
long-term efficacy and cost-effectiveness. 
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